Progression-free and overall survival data from Companion-002 are due this quarter.
ApexOnco Front Page
Recent articles
JSKN027 will become the first ADC with this mechanism to enter human trials.
But the Astra/Daiichi ADC stumbles in lung cancer.
First-in-human listings bring a bispecific and yet another in vivo Car-T.
The company is starting four new pivotal trials this year.
The company quietly deprioritises AlphaMedix.
Cafelkibart’s entry into phase 3 is of note to Coherus.
Tecvayli and Hernexeos might get speedy approval decisions.
